High manufacturing costs are a significant barrier to patient access to CAR T cell therapies, according to recent research. However, decentralization, vector-free modification technologies, and artificial intelligence (AI) might pave the way for more cost-effective production.
The Cost Conundrum
Manufacturing CAR T therapies is notoriously expensive. A study indicates that producing a single batch can cost between $170,000 and $220,000. These costs are primarily driven by the logistical, processing, and distribution steps involved.
Martin Bonamino, PhD, leader of the experimental cancer immunotherapy group at Brazil’s National Cancer Institute (INCA), identifies the centralized manufacturing model as a fundamental problem. “CAR T cell therapy is disruptive and involves new production processes. The current model in the pharmaceutical industry is one of centralized production, which involves many logistics and structural costs. In this sense, local strategies, such as point-of-care (POC) production, can help reduce this complexity,” he explains.
Point-of-Care Production
POC production involves creating the therapy at the hospital or clinic where it will be administered, rather than at a remote site. For CAR T therapies, the benefits are apparent. Bonamino states, “POC can undoubtedly simplify logistics, deliver cells to the patient at more appropriate times, and serve locations that can function as hubs for large regions.”
Cost Reduction Strategies
Bonamino and his colleagues advocate for POC manufacturing, arguing that eliminating logistics-related expenses could significantly reduce the cost of goods (COGs). However, decentralization is not the sole opportunity for cost reduction. Bonamino highlights efforts to replace viral vectors in CAR T production with CRISPR, nanoparticle, and mRNA-based methods as highly promising.
“Currently, several groups are developing strategies that do not use viral vectors, which would have a significant impact as vectors are one of the most expensive items in the process,” he notes.
Additionally, some researchers are exploring the use of nanoparticles filled with genetic material to convert circulating T cells into CAR T cells within the patient, in vivo. This method, currently being tested in preclinical models, could remove the need for laboratory cell manipulation. Bonamino points out that while this approach is promising, “the balance of risk, effectiveness, and costs has yet to be evaluated.”
The Role of Artificial Intelligence
Artificial intelligence is also poised to play a crucial role in reducing CAR T production costs. According to Bonamino, the most promising applications are in process development and product design.
“AI can help us design better CAR Ts, search for novel response biomarkers, and find more efficient manufacturing processes,” he says. The integration of AI could revolutionize the way CAR T therapies are developed and produced, making them more accessible to a broader range of patients.
Future Perspectives
The combination of decentralization, innovative vector-free technologies, and AI holds the potential to transform the CAR T cell therapy landscape. By addressing the high costs associated with production, these advancements could make life-saving treatments more accessible to patients worldwide.
For continued updates and insights into the evolving world of biomanufacturing and artificial intelligence, follow aitechtrend.com.
Note: This article is inspired by content from . It has been rephrased for originality. Images are credited to the original source.